Fludarabine
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Fludarabine
- Molecular weight
- 285.24
- Structure (SMILES)
- Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
- 2 f araa
- 2 fluoro 9 beta d arabinofuranosyladenine
- 2 fluoro ara a
- 2 fluorovidarabine
- 2-f-araa
- 2-fluoro ara-a
- 2-FLUORO-9-.BETA.-D-ARABINOFURANOSYLADENINE
- 2-fluorovidarabine
- 9 beta d arabinofuranosyl 2 fluoro 9h purin 6 amine
- 9 beta d arabinofuranosyl 2 fluoroadenine
- 9-.BETA.-D-ARABINOFURANOSYL-2-FLUORO-9H-PURIN-6-AMINE
- 9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE
- fludarabina
- Fludarabina
- fludarabine
- Fludarabine
- FLUDARABINE [HSDB]
- fludarabine [INN]
- FLUDARABINE [MI]
- FLUDARABINE [VANDF]
- Fludarabine [WHO-DD]
- fludarabine hsdb
- fludarabine inn
- fludarabine mi
- fludarabine phosphate impurity 2 fluoro ara adenine usp impurity
And 11 more, listed on the interactive page.
- ATC classification codes
- L01BB05
Sources for recorded values
- CAS registry numbers
- 21679-14-1
- ChEMBL ID
- CHEMBL1568
- InChIKey
- HBUBKKRHXORPQB-FJFJXFQQSA-N
- PubChem compound IDs
- 657237
- RxNorm IDs (RxCUI)
- 24698
- FDA ingredient codes (UNII)
- P2K93U8740
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- fludarabine
- Type
- Synthetic organic
- Drug name stem
- -arabine
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ribonucleotide reductase catalytic subunit M1
- Gene symbol
- RRM1
- Protein identifier
- P23921
- Median affinity
- 6
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ribonucleotide reductase regulatory subunit M2
- Gene symbol
- RRM2
- Protein identifier
- P31350
- Median affinity
- 6
- Affinity units
- pIC50
- Primary target
- Yes
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Sarcoma, Ewing
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000174
- Subject identifier
- D012512
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Lymphoma, B-Cell, Marginal Zone
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000191
- Subject identifier
- D018442
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Crohn Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Leukemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
And 93 more, listed on the interactive page.
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000096
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000198
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000220
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000339
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000565
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002617
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003863
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004251
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004352
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004599
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005952
- Highest recorded phase
- 3
And 267 more, listed on the interactive page.
- Event
- acute graft versus host disease
- Reports
- 435
- Reporting signal score
- 1,606.97
- Event
- acute graft versus host disease in intestine
- Reports
- 114
- Reporting signal score
- 425.42
- Event
- acute graft versus host disease in skin
- Reports
- 298
- Reporting signal score
- 1,171.09
- Event
- acute lymphocytic leukaemia recurrent
- Reports
- 64
- Reporting signal score
- 168.792
- Event
- acute myeloid leukaemia
- Reports
- 164
- Reporting signal score
- 324.044
- Event
- acute myeloid leukaemia recurrent
- Reports
- 53
- Reporting signal score
- 170.905
- Event
- adenovirus infection
- Reports
- 207
- Reporting signal score
- 751.051
- Event
- autoimmune haemolytic anaemia
- Reports
- 126
- Reporting signal score
- 334.285
- Event
- bacteraemia
- Reports
- 145
- Reporting signal score
- 244.925
- Event
- bk virus infection
- Reports
- 135
- Reporting signal score
- 372.819
- Event
- bone marrow failure
- Reports
- 220
- Reporting signal score
- 288.649
- Event
- bronchopulmonary aspergillosis
- Reports
- 139
- Reporting signal score
- 323.895
- Event
- chronic graft versus host disease
- Reports
- 272
- Reporting signal score
- 901.545
- Event
- chronic graft versus host disease in skin
- Reports
- 48
- Reporting signal score
- 143.811
- Event
- chronic lymphocytic leukaemia
- Reports
- 78
- Reporting signal score
- 169.818
- Event
- chronic lymphocytic leukaemia recurrent
- Reports
- 199
- Reporting signal score
- 886.222
- Event
- cystitis haemorrhagic
- Reports
- 195
- Reporting signal score
- 585.075
- Event
- cytokine release syndrome
- Reports
- 494
- Reporting signal score
- 1,537.74
- Event
- cytomegalovirus chorioretinitis
- Reports
- 66
- Reporting signal score
- 170.463
- Event
- cytomegalovirus infection
- Reports
- 629
- Reporting signal score
- 1,744.25
- Event
- cytomegalovirus infection reactivation
- Reports
- 211
- Reporting signal score
- 756.221
- Event
- cytomegalovirus viraemia
- Reports
- 192
- Reporting signal score
- 568.042
- Event
- cytopenia
- Reports
- 119
- Reporting signal score
- 192.716
- Event
- dizziness
- Reports
- 64
- Reporting signal score
- 150.013
- Event
- engraftment syndrome
- Reports
- 70
- Reporting signal score
- 275.037
And 34 more, listed on the interactive page.
- NCT00001422
- NCT00003552
- NCT00338377
- NCT00509288
- NCT00923195
- NCT00924001
- NCT01585415
- NCT01883323
- NCT01946373
- NCT02111863
- NCT02621021
- NCT03166397
- NCT06190249
- NCT00004485
- NCT00040417
- NCT00408447
- NCT00489281
- NCT00968162
- NCT01850108
- NCT01877837
- NCT02435901
- NCT02678143
- NCT02766465
- NCT03121001
- NCT03263559
And 520 more, listed on the interactive page.
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 4
- Polar surface area
- 139.54
- Calculated partition coefficient (ALogP)
- -1.84
- Calculated partition coefficient (XLogP)
- -0.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 20
- Molecular formula
- C10H12FN5O4
- Monoisotopic mass
- 285.08733204
- Natural product
- No
- Recorded assays
- 2,609
- Active assays
- 306
- Confirmatory
- Other
- Screening
- Summary
- Antineoplastic Agents
Related records
Trials (1,227)
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
- A Controlled Trial of Intermittent Fludarabine for Psoriatic Arthritis
- A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
- A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma
- A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy
- A Phase 1 Study of ADI-001 in B Cell Malignancies
- A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
- A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
In development for (257)
- Acquired idiopathic inflammatory myopathy Phase 1
- Acquired polycythemia vera Phase 2
- Acute erythroid leukemia Phase 2
- Acute leukemia Phase 2
- Acute leukemia of ambiguous lineage Phase 1
- Acute lymphoblastic leukemia Phase 3
- Acute myeloid leukemia Phase 3
- Adult T-cell leukemia/lymphoma Phase 1
- AL amyloidosis Phase 1
- Alveolar rhabdomyosarcoma Phase 2
- Alveolar soft part sarcoma Phase 1
- Anal carcinoma Phase 2
- Anal squamous cell carcinoma Phase 2
- Anaplastic large cell lymphoma Phase 1
- Anemia Phase 1
- Angioimmunoblastic T-cell lymphoma Phase 2
- Anti-neutrophil cytoplasmic antibody-associated vasculitis Phase 1
- Antisynthetase syndrome Phase 2
- Aplastic anemia Phase 3
- Autoimmune disease Phase 1
Other linked conditions (1)
- High grade B-cell lymphoma